To help tackle the current COVID-19 crisis and its aftermath, the AXA Research Fund has committed to further support research in the area of pandemics and infectious diseases, as well as related post crisis challenges. Furthermore, with over 650 research projects focussed on the interdependent challenges our planet faces today, the Fund is well positioned to shed light on and determine the best responses to its extraordinary fallout.

The AXA Research Fund will earmark 5M Euro of its project funding budget to further develop responses to infectious diseases and COVID-19, including post-crisis solution building.

Key areas of support will include: helping low-and middle-income countries strengthen their primary health care systems and infrastructure including early warning systems; the development of safe and effective vaccines and antivirals; the study of the economic and social consequences of the crisis as well as the corollary solutions - especially on vulnerable populations; the continued support to climate and biodiversity research and their related effects on health, disease and epidemics.

This 5M Euro commitment adds up to a 7.4M Euro already dedicated to over 35 projects from top tier institutions  in the area of infectious diseases and pandemics.

In early March 2020, the AXA Research Fund was the first funder of the Pasteur Institute COVID-19 Task Force, dedicated to understanding the virus and its pathogenesis; developing new diagnostic tools and vaccine candidates; searching for antibodies that may have therapeutic applications; developing & modeling epidemiology and drafting outbreak control strategies. This brought the Fund’s total support to the world-renowned Pasteur Institute to over 2M Euro.

The AXA Research Fund also supports the Open COVID-19 initiative by JOGL (Just One Giant Lab), an open source platform created by former AXA Fellow Thomas Landrain. So far, more than 3,000 contributors including engineers, researchers and computer scientists have joined the program from all continents and are working in open source mode to develop solutions in diagnostics, therapy and treatment, with a focus on low-cost solutions to respond to the crisis, including masks, ventilators and diagnosis tests.

The AXA Research Fund also supports the new JEDI Covid-19 challenge launched by the Joint European Disruptive Initiative (JEDI). This challenge invites scientific teams to screen billions of molecules with blocking interactions relevant to SARS-CoV-2, and fast-track the route to a therapeutic treatment.

This new commitment to additional support on infectious diseases and pandemics will bring the AXA Research Fund’s financial support in this area to over 13M Euros.

April 2020

Institut Pasteur Task Force

The AXA Research Fund strengthens its support to the Institut Pasteur


JOGL' OpenCOVID-19 initiative

A pluri-disciplinary, open-source response to the crisis


Billion Molecules against COVID-19 Grand Challenge

The AXA Research Fund has committed to support this Grand Challenge launched by the Joint European Disruptive Initiative (JEDI)


Learn more about research that include the COVID19 thematic

Why shutting down Chinese ‘wet markets’ could be a terrible mistake
The role of Chinese ‘wet markets’ is central to the spread of coronavirus. Discover Dr. Frédéric Keck's perspective
Domestic abuse: how to help someone you think might be at risk
How can we help women who face domestic abuse? Dr. Alison Gregory shares insights and advice from her research
5 tips for our mental health
Feeling good can reduce our stress and improve our health. Dr. Sarah Pressman gives us 5 tips to manage stress and be happy
Fighting an emerging invasive pathogen from Asia
Prof. Dirk Schmeller highlights some similarities between a largely unknown pathogen devastating amphibian populations and the covid-19 virus claiming the lives of humans
How to restart the COVID-Lockdown Economy
As the toll on human health and lives caused by the novel coronavirus increases daily, economy-wide lockdowns are severely impacting the economy. Discover Prof. Lily Fang's argues